Natera reports WCLC dataset of Signatera MRD in NSCLC
Natera announced WCLC data from 1,129 resected stage 1-3 NSCLC patients, saying Signatera MRD status predicts recurrence-free and overall survival in early post-surgical and surveillance settings.
Natera said WCLC data from 1,129 resected stage 1-3 NSCLC patients showed Signatera MRD status predicted recurrence-free survival and overall survival in early post-surgical and surveillance settings.